Actively Recruiting
Phase I Evaluation of SNE-101 Stem Cell-Derived Therapy for Adults With Acute Ischemic Stroke Assessing Safety and Tolerability
Led by S&Ebio Co. Ltd. · Updated on 2026-07-06
18
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and early effects of SNE-101, an extracellular vesicle derived from Whartons jelly mesenchymal stem cells, in adults who have experienced an acute ischemic stroke. This phase I, open-label, single-arm, dose escalation trial aims to determine the maximum tolerated dose and assess preliminary efficacy in this patient group. Participants will receive intravenous infusions of SNE-101 once daily for 5 days. The study includes three cohorts receiving escalating doses of SNE-101, with each cohort consisting of 3 to 6 participants. The trials primary focus is on safety and tolerability within 19 days after the first dose and monitoring adverse events for up to 180 days. During the study, participants will be closely monitored through neurological assessments and imaging to evaluate stroke effects and treatment impact. Safety evaluations will continue for several months, and efficacy will be assessed over 13 weeks. Participants will provide informed consent before enrollment, and their neurological status and imaging will be regularly reviewed throughout the trial period.
CONDITIONS
Brief Title
The STem Cell-derived Extracellular Vesicle Therapy In Acute Ischemic Stroke (STEVIA)
Research Team
O
Oh Young Bang, MD, Ph.D
S
SeungWoo Yeon, Ph.D
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here